Isaac Francis

The Australian dollar powered to fresh heights on Feb. 13, fueled by a significant widening in yield spreads.

WT Financial Group (ASX:WTL) posted a robust set of indicative results for the first half of FY26, underscoring a period of significant operational momentum.

Marmota (ASX:MEU) has secured firm commitments to raise $15 million through a single-tranche placement.

Paladin Energy (ASX:PDN) reported a robust revenue of US$138.3 million in H1 FY26, underpinned by the sale of 1.96Mlb of triuranium octoxide at an average realised price of US$70.5/lb.

Agios Pharmaceuticals (NASDAQ:AGIO) today released financial results and business updates for the fourth quarter and full year ended December 31, 2025, highlighting regulatory progress and commercial momentum in rare blood disorders.

Northern Star Resources (ASX:NST) reported a net profit after tax of $714 million for H1 FY26, representing a sharp 41% increase compared to the previous corresponding period.

AMP (ASX:AMP) has delivered a robust financial performance for the 2025 fiscal year, headlined by a 20.8% rise in underlying net profit after tax, reaching $285 million.

Upstream Bio (NASDAQ:UPB) announced breakthrough results for its lead candidate, verekitug, in a mid-stage trial that could disrupt the multibillion-dollar biologics market for severe respiratory diseases.

NiSource (NYSE:NI) signaled a fundamental shift in its growth trajectory today, reporting record 2025 results alongside a transformative capital plan that hitches the utility’s future to the burgeoning AI and data center sector.

Merck (NYSE:MRK) reached a historic milestone in oncology today as the FDA approved KEYTRUDA (pembrolizumab) and its new subcutaneous twin, KEYTRUDA QLEX, for the treatment of platinum-resistant ovarian cancer.